Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis

• Results Overview

  Several new biologic medications (lebrikizumab, tralokinumab, fezakinumab, nemolizumab, and GBR 830) showed promising results in treating moderate-to-severe atopic dermatitis in adults, while two others (tezepelumab and etokimab) did not show significant improvements.

• Study Summary

  Num Participants:

  None

  Study Type:

  Review

  Control Group:

  None

  Efficacy End Points Treatment:

  None

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected